BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 27020861)

  • 21. Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells.
    Duan L; Calhoun S; Shim D; Perez RE; Blatter LA; Maki CG
    J Mol Cell Biol; 2021 Sep; 13(6):433-444. PubMed ID: 33755174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway.
    Wu C; Luo J
    Med Sci Monit; 2016 Oct; 22():3860-3867. PubMed ID: 27765938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiestrogenic effect of 20S-protopanaxadiol and its synergy with tamoxifen on breast cancer cells.
    Yu Y; Zhou Q; Hang Y; Bu X; Jia W
    Cancer; 2007 Jun; 109(11):2374-82. PubMed ID: 17464948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells.
    Scotland S; Saland E; Skuli N; de Toni F; Boutzen H; Micklow E; Sénégas I; Peyraud R; Peyriga L; Théodoro F; Dumon E; Martineau Y; Danet-Desnoyers G; Bono F; Rocher C; Levade T; Manenti S; Junot C; Portais JC; Alet N; Récher C; Selak MA; Carroll M; Sarry JE
    Leukemia; 2013 Nov; 27(11):2129-38. PubMed ID: 23568147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tamoxifen inhibits ER-negative breast cancer cell invasion and metastasis by accelerating Twist1 degradation.
    Ma G; He J; Yu Y; Xu Y; Yu X; Martinez J; Lonard DM; Xu J
    Int J Biol Sci; 2015; 11(5):618-28. PubMed ID: 25892968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tamoxifen treatment promotes phosphorylation of the adhesion molecules, p130Cas/BCAR1, FAK and Src, via an adhesion-dependent pathway.
    Cowell LN; Graham JD; Bouton AH; Clarke CL; O'Neill GM
    Oncogene; 2006 Dec; 25(58):7597-607. PubMed ID: 16799644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1.
    Ming J; Ruan S; Wang M; Ye D; Fan N; Meng Q; Tian B; Huang T
    Oncotarget; 2015 Dec; 6(38):40692-703. PubMed ID: 26517687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclooxygenase-2 utilizes Jun N-terminal kinases to induce invasion, but not tamoxifen resistance, in MCF-7 breast cancer cells.
    Gonzalez-Villasana V; Gutiérrez-Puente Y; Tari AM
    Oncol Rep; 2013 Sep; 30(3):1506-10. PubMed ID: 23783392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
    Zhang X; Wang ZY
    Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated Hexokinase II Expression Confers Acquired Resistance to 4-Hydroxytamoxifen in Breast Cancer Cells.
    Liu X; Miao W; Huang M; Li L; Dai X; Wang Y
    Mol Cell Proteomics; 2019 Nov; 18(11):2273-2284. PubMed ID: 31519767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trichostatin A and Tamoxifen inhibit breast cancer cell growth by miR-204 and ERα reducing AKT/mTOR pathway.
    Liu J; Li Y
    Biochem Biophys Res Commun; 2015 Nov; 467(2):242-7. PubMed ID: 26436206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
    Gökmen-Polar Y; Toroni RA; Hocevar BA; Badve S; Zhao Q; Shen C; Bruckheimer E; Kinch MS; Miller KD
    Breast Cancer Res Treat; 2011 Jun; 127(2):375-84. PubMed ID: 20602165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity.
    Shah YM; Rowan BG
    Mol Endocrinol; 2005 Mar; 19(3):732-48. PubMed ID: 15528270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer.
    Mishra RR; Belder N; Ansari SA; Kayhan M; Bal H; Raza U; Ersan PG; Tokat ÜM; Eyüpoğlu E; Saatci Ö; Jandaghi P; Wiemann S; Üner A; Cekic C; Riazalhosseini Y; Şahin Ö
    Clin Cancer Res; 2018 Apr; 24(8):1987-2001. PubMed ID: 29386221
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
    Fumarola C; Caffarra C; La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Galvani E; Generali D; Petronini PG; Bonelli MA
    Breast Cancer Res Treat; 2013 Aug; 141(1):67-78. PubMed ID: 23963659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SR4 Uncouples Mitochondrial Oxidative Phosphorylation, Modulates AMP-dependent Kinase (AMPK)-Mammalian Target of Rapamycin (mTOR) Signaling, and Inhibits Proliferation of HepG2 Hepatocarcinoma Cells.
    Figarola JL; Singhal J; Tompkins JD; Rogers GW; Warden C; Horne D; Riggs AD; Awasthi S; Singhal SS
    J Biol Chem; 2015 Dec; 290(51):30321-41. PubMed ID: 26534958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma.
    Ma J; Guo Y; Chen S; Zhong C; Xue Y; Zhang Y; Lai X; Wei Y; Yu S; Zhang J; Liu W
    BMC Cancer; 2014 Mar; 14():172. PubMed ID: 24612549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aromatase and breast cancer.
    Brodie A; Sabnis G; Jelovac D
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.